Slide 1: InspireMD
inspireMD
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements." Such statements may be preceded by the words “intends, ‘may. ‘wil’ “plans,’ “expects,” “anticipates” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential or similar words. Forwarc-looking stat
Slide 3: MGuard designed to transform the current standard of care
MGuard™ designed to transform the current standard of care 25,000 stents sold; Physician driven Data to date compares favorably to published standard of care data $1.78 market, addressing unmet need Favorable demographics for growth Currently selling in 30 countries; CE Mark clearance 2007 & 2010 ~$
Slide 4: To become a global leader in vascular disease treatment
To become a global leader in the development and commercialization of innovative and breakthrough technologies in vascular disease treatment 4 inspireMD
Slide 5: Coronary Stent Market
Coronary Stent Market + Inadequate outcomes, as current stents designed primarily for Stable Angina A population 2B Stable + Majority of AMI market is ex-US, Angina/Other commercialization initiated in 30 countries + Additional potential upside of $0.3B in SVG (Saphenous Vein Graft) market * Source:
Slide 6: Minor heart attack treated with a Bare Metal Stent or Drug Eluting Stent
Minor heart attack treated with a Bare Metal Stent (BMS) or Drug Eluting Stent (DES) implant Pre Procedure. | Debris to flow down stream, occluding small arteries “Downstream Embolization” Embolization inspireMD
Slide 7: Proprietary design, flexible structure and construction
Proprietary design, flexible structure and construction leads to profound biological implications @ Minimal inflammation @ Minimal foreign body reaction @ Does not promote thrombosis iter Emboli inspire
Slide 8: MGuard: Addressing the Acute MI Market
MGuard™ Addressing the Acute MI Market MicroNet™ Technology Encasing a Stent Proprietary design attributes allow for the capture of debris and prevention of embolization downstream . inspireMD
Slide 9: Design Highlights
Design Highlights Embolic Protection Safer procedures by filtering plaque and debris 9 inspireMD
Slide 10: MicroNet Technology Integrated with Stent
MicroNet™ Technology Integrated with Stent. Euro PCR Symposium, 2011 Qnline Video of InspireMD's MGuard 10 inspireMD
Slide 11: Single-Arm Trials, Patients Acute MI/ST Segment Elevation
11 Single-Arm Trials, 630 Patients 458 Acute MI/ST Segment Elevation Myocardial Infarction (STEMI) Patients* Major Parameters Tested * Blush Grade ( *Reflect amount of ») * ST Segment Resolution reperfusion to the * Major Adverse Cardiac Events (MACE) pe | MACE rooled Vata Analysis vie od — di Resul
Slide 12: A Predictor for Adverse Events
A Predictor for Adverse Events 42% fod ae 31% a... BMS TA. MGuard ams TA BMS TA MGuard 0-1 2 Unsuccessful Result Data on this slide for BMS, ‘and MiGuard are de ram diferent sources, Please note head to head st snot been cond [BMS (N-66S, TAPAS & EXPORT Trae) 3, TAPAS & EXPORT Trial Apiration arm) _
Slide 13: A Predictor for Adverse Events
A Predictor for Adverse Events MGuard™ vs. Historical BMS/Aspiration AMI Trials 79.6% 56.6% 37.9% 30.8% 12.6% 1.3% | MSTA. MGuard. BMS TA MGuard BMS TA MGuard <30 30-70 >70 Unsuccessful Result ] Optimal Result Data on this slide for BMS, TA and MGuard are derived from diferent zources Please notes h
Slide 14: MICAMI Results
| Results Objective: To assess the efficacy of MGuard in microvascular reperfusion impairment during primary PCI, compared with bare metal stents (BMS). Method: STEMI patients in 3 Chilean centers, randomized for MGuard (n = 20) or a bare metal stent (n = 20). Blinded experts performed off-line anal
Slide 15: MACE comparison of BMS, TA and MGuard
5.9% 2.4% 30D 1 2 3Y Data onthe slide for BMS, TA and MGuard are derived from diferent zources Please notes hea to head study hae not been conducted, MACE = Cardiac death Ml, and TLR 415 8MS HORIZONS AMitral BMSarm — MGuard, Magica, Piscione, Weerackody, MOS —“‘e DES, HORIZONS Atl rial DES am 14 (20
Slide 16: Post Marketing Trial, Ex US
Post Marketing Trial, Ex US Enrollment Objective 16 Start: Q3/2011, End: Q2/2012 Evaluate MGuard compared to BMS and DES in achieving better myocardial reperfusion Increase in frequency of complete ST resolution Blush, TIMI, and MACE at 30 days, 6 months, 1 year 432, STEMI, Randomized 1:1, MGuard ™
Slide 17: Registration Trial
Registration Trial Start: Q4 2012, End: H1 2014 Evaluate safety and efficacy of MGuard vs. BMS in STEMI/AMI Efficacy: Superiority in myocardial reperfusion: Increase in BLUSH Grade 3 (MBG3) Safety: Non inferiority in TVF (Target Vessel Failure) MACE at 1 year, TIMI, and ST segment resolution 880, ST
Slide 18: FDA Trial Timeline
© 432 patients, Randomized 1:1 vs. BMS/DES © Primary end point - ST Segment resolution |carova Carots ear Gu- Sinn Top Line Data Announcement ‘Trial Trial on Recruitment Initiation| peg ial +—— © 880 patients (pending), Randomized 2:1 vs. BMS © Co-primary end points - Superiority in MBG3, Non-inferi
Slide 19: MGuard MicroNet Technology Peripheral
MGuard™ MicroNet™ Technology Peripheral* Planned product =" 19 Inspire!
Slide 20: Building on InspireMD's Platform Technology
Building on InspireMD’s Platform Technology” Addressable Market Sold in E <a =m —e 20. * Source: Health Research international, (January 2012) inspirelMD Product Product Stage
Slide 21: Patents Filed in US and Overseas
21 Patents Filed in US and overseas 9 Patents (1 granted, 8 pending) Stent platform: US Freedom to Operate legal opinion IP Counsel: Wilson, Sonsini, Goodrich & Rosati IP protects Key Attributes of MicroNet™ Technology inspireMD
Slide 22: Management Team
(Chaim Lotan, M.D. FACGFESC Medical Director Hebrew Universty ‘Hadassah Medial Center El Bar, 88e cro *Product development RED infastrecture “Fully implantable VAD patent fir Paz, MSEEMBA ceo Previous experiance Founder, Peach Networks microsoh *IOF Ofcer crag Shore, MBA cro Robert Rati, MSe VP Sale
Slide 23: Board of Directors
Board of Directors 01 Barer; PHO Chairman of he Board Former Chasman and — (CEO, Celgene, (NASO: ces) James Bary “EVP ana C00, Previous experence “Nice Presient Corporate Reseach fra Advanced ‘Teennelony Development t Boston Seni os Ptaer 23 ofr Paz, Asher Holzer, PRO MSEEMBA Co-Founder (Co-Founder
Slide 24: Scientific and Clinical Advisors
Prot. Alexandre A. Abizald + Chet of Coronary Interventions at istiute Dante Pazzanese de Cardloga in S80 Paulo, Braz + Associate rector of TCT (Columbia Unversity, us) 1. Yaron Almagor = etor of Cardiac Catheterization and Intewentonel Cardiology Laboratories at sesselson Heart Center Shaare Zecek
Slide 25: NSPR.OB Financial Summary
NSPR.OB Sin Thousands ‘SMonths Ended Year Ended December 31, 2012 2011 2011 2010 Income Statement Total Revenue 1.138 1686 6,004 4,949 Cost of Revenues 874 899 aon 2.696 Expenses Research and Development 1349 343 2.474 1338 Sales and Marketing 405 428 4973 1,236 General and Administrative 1.896 a1a6
Slide 26: Novel Stent Technology
Novel Stent Technology Core technology aim to change standard of care, 25k sold to date $1.78 dollar initial market, potential to be standard of care 30 countries, physician driven, Patents filed covering all relevant aspects, Freedom to Operate * Prior expertise with Microsoft, Boston Scientific, A
Slide 27: Thank You
27 Thank You inspireMD